CEL SCI CORP
For the period ended Sep 30, 2025. Filed Dec 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 29, 2025
CVM$1.41+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| 2025 | 2024 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(25,411,055) | $(26,920,465) |
| Adjustments to reconcile net loss to | ||
| net cash used in operating activities: | ||
| Depreciation and amortization | 3,885,153 | 3,969,183 |
| Non-cash lease expense, net of lease payments | (5,812) | 4,873 |
| Share-based payments for services | 754,673 | 858,498 |
| Equity based compensation | 1,910,997 | 4,270,180 |
| Common stock contributed to 401(k) plan | 218,317 | 218,717 |
| Shares issued for settlement of clinic development costs | 350,885 | - |
| Loss on patent impairment | 18,275 | - |
| (Increase)/decrease in assets: | ||
| Prepaid expenses | (42,550) | 72,674 |
| Supplies used for R&D and manufacturing | 973,665 | (172,608) |
| Deposits | (3,585) | 745 |
| Increase/(decrease) in liabilities: | ||
| Accounts payable | (442,710) | (460,576) |
| Accrued expenses | 120,728 | (458,489) |
| Due to employees | 553,282 | (193,938) |
| Net cash used in operating activities | (17,119,737) | (18,811,206) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (38,109) | (94,875) |
| Expenditures for patent costs | - | (13,211) |
| Net cash used in investing activities | (38,109) | (108,086) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 28,291,100 | 23,575,000 |
| Payments of stock issuance costs | (3,126,779) | (2,370,513) |
| Proceeds from the purchase of stock by officers and directors | 219,995 | 80,620 |
| Payments on obligations under finance leases | (2,011,183) | (1,773,377) |
| Proceeds from related party loans | - | 450,000 |
| Payments of related party loans | - | (450,000) |
| Proceeds from notes payable | 350,000 | - |
| Payments of notes payable | (350,000) | - |
| Net cash provided by financing activities | 23,373,133 | 19,511,730 |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 6,215,287 | 592,438 |
| CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR | 4,738,173 | 4,145,735 |
| CASH AND CASH EQUIVALENTS, END OF YEAR | $10,953,460 | $4,738,173 |
STATEMENTS OF CASH FLOWS
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
| 2025 · 2024 | |||
|---|---|---|---|
| Property and equipment purchases included in current liabilities | $ | - | $32,954 |
| Assets purchased under finance leases | $ | - | $20,797 |
| Finance lease obligation included in accounts payable | $1,133 | $1,320 | |
| Obligations paid with issuance of common stock | $750,328 | $759,901 | |
| Financing costs included in current liabilities | $152,735 | $38,950 | |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOWS: | |||
| Cash paid for interest | $768,466 | $923,807 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.